Suppr超能文献

PARP抑制剂在神经肿瘤学中的潜力。

The potential of PARP inhibitors in neuro-oncology.

作者信息

Carruthers Ross, Chalmers Anthony J

机构信息

Institute of Cancer Sciences, University of Glasgow, Switchback Road, Bearsden, Glasgow G12 8QQ, UK.

出版信息

CNS Oncol. 2012 Sep;1(1):85-97. doi: 10.2217/cns.12.13.

Abstract

DNA damaging agents have an integral role in the treatment of brain tumors. Recent advances in our understanding of how cancer cells repair DNA damage have made it possible to consider modification of the DNA damage response as a way in which resistance to radiotherapy and chemotherapy might be overcome. PARP inhibitors are potent but nontoxic drugs that inhibit repair of DNA single-strand breaks and increase the cytotoxic effects of radiotherapy and alkylating chemotherapy agents, including temozolomide. PARP inhibitors have potential applications in neuro-oncology because there is increasing evidence that their radio- and chemo-sensitizing effects are tumor specific. This review explores the mechanisms of action of PARP inhibitors and describes their putative mechanisms of radio- and chemo-sensitization in the context of CNS oncology. The authors go on to review their development in recent clinical trials, with a focus on glioblastoma.

摘要

DNA损伤剂在脑肿瘤治疗中起着不可或缺的作用。近年来,我们对癌细胞如何修复DNA损伤的认识取得了进展,这使得将DNA损伤反应的调节视为克服放疗和化疗耐药性的一种方法成为可能。PARP抑制剂是一类强效但无毒的药物,可抑制DNA单链断裂的修复,并增强放疗和包括替莫唑胺在内的烷化化疗药物的细胞毒性作用。PARP抑制剂在神经肿瘤学中具有潜在应用价值,因为越来越多的证据表明它们的放射增敏和化学增敏作用具有肿瘤特异性。本文综述了PARP抑制剂的作用机制,并在中枢神经系统肿瘤学背景下描述了其假定的放射增敏和化学增敏机制。作者接着回顾了它们在近期临床试验中的进展,重点是胶质母细胞瘤。

相似文献

1
The potential of PARP inhibitors in neuro-oncology.
CNS Oncol. 2012 Sep;1(1):85-97. doi: 10.2217/cns.12.13.
2
Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors.
Anticancer Agents Med Chem. 2010 Sep;10(7):520-33. doi: 10.2174/187152010793498627.
3
Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.
Semin Radiat Oncol. 2010 Oct;20(4):274-81. doi: 10.1016/j.semradonc.2010.06.001.
4
PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Free Radic Biol Med. 2009 Jul 1;47(1):13-26. doi: 10.1016/j.freeradbiomed.2009.04.008. Epub 2009 Apr 10.
6
Development of PARP inhibitors in oncology.
Expert Opin Investig Drugs. 2009 Jan;18(1):31-43. doi: 10.1517/13543780802525324.
7
[PARP inhibitors--theoretical basis and clinical application].
Postepy Hig Med Dosw (Online). 2012 May 30;66:311-21. doi: 10.5604/17322693.999033.
8
[PARP inhibitors: significant progress in cancer therapy].
Bull Cancer. 2011 Mar;98(3):277-90. doi: 10.1684/bdc.2011.1330.
9
The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.
Curr Drug Targets. 2011 Dec;12(14):2034-44. doi: 10.2174/138945011798829438.
10
The role of PARP in DNA repair and its therapeutic exploitation.
Br J Cancer. 2011 Oct 11;105(8):1114-22. doi: 10.1038/bjc.2011.382.

引用本文的文献

1
Brain metastases in patients with metastatic breast cancer and BRCA1/2 mutations in cell-free DNA.
Breast Cancer Res Treat. 2025 Jul;212(1):107-112. doi: 10.1007/s10549-025-07705-7. Epub 2025 Apr 25.
2
Advances in Treatment of Diffuse Midline Gliomas.
Curr Neurol Neurosci Rep. 2023 Dec;23(12):849-856. doi: 10.1007/s11910-023-01317-8. Epub 2023 Nov 3.
3
Therapeutic Options for Brain Metastases in Gynecologic Cancers.
Curr Treat Options Oncol. 2022 Nov;23(11):1601-1613. doi: 10.1007/s11864-022-01013-8. Epub 2022 Oct 18.
4
Medulloblastoma and the DNA Damage Response.
Front Oncol. 2022 Jun 7;12:903830. doi: 10.3389/fonc.2022.903830. eCollection 2022.
6
Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases.
Cancers (Basel). 2022 Jan 29;14(3):687. doi: 10.3390/cancers14030687.
7
Enhancing Career Paths for Tomorrow's Radiation Oncologists.
Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):52-63. doi: 10.1016/j.ijrobp.2019.05.025. Epub 2019 May 22.

本文引用的文献

1
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
N Engl J Med. 2012 Apr 12;366(15):1382-92. doi: 10.1056/NEJMoa1105535. Epub 2012 Mar 27.
2
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.
Nat Biotechnol. 2012 Feb 19;30(3):283-8. doi: 10.1038/nbt.2121.
3
DNA repair mechanisms protect our genome from carcinogenesis.
Front Biosci (Landmark Ed). 2012 Jan 1;17(4):1362-88. doi: 10.2741/3992.
5
Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
Mol Cancer Ther. 2011 Oct;10(10):1949-58. doi: 10.1158/1535-7163.MCT-11-0278. Epub 2011 Aug 8.
6
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.
Br J Cancer. 2011 Aug 23;105(5):628-39. doi: 10.1038/bjc.2011.240. Epub 2011 Jul 19.
8
Glioblastoma multiforme stem cells.
ScientificWorldJournal. 2011 Apr 19;11:930-58. doi: 10.1100/tsw.2011.42.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验